X

Trial Profile

A Study of SGN-PDL1V in Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SGNPDL 1V (Primary)
Indications Advanced breast cancer; Carcinoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; First in man
Sponsors Seagen

Most Recent Events

19 Aug 2024 Planned number of patients changed from 332 to 438.
31 Jan 2024 Planned number of patients changed from 315 to 332.
31 Jan 2024 Patients with gastric cancer are now eligible to participate in this trial after the protocol was modified to include a treatment arm and expand the patient group.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com